That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
NervGen has announced that the first participant has been dosed in RESTORE, a Phase 3 study assessing NVG-291 for improving hand function and quality of life in individuals with chronic cervical motor-incomplete spinal cord injury. The study builds on previous positive results from the CONNECT SCI trial and is aligned with FDA guidelines. Enrollment completion is expected in the second half of 2027, with topline data anticipated by the first half of 2028.
Written locally by qwen2.5:14b on 2026-10-12,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
NervGen, a biopharmaceutical company focused on neuroreparative therapies, announced that the first patient has been enrolled in RESTORE, a Phase 3 study for NVG-291, a drug aimed at improving hand function and quality of life for individuals with chronic cervical motor-incomplete spinal cord injuries. This trial builds upon earlier positive results from the Phase 1b/2a CONNECT SCI study, which showed functional improvements. The FDA has aligned with this design for the Phase 3 registrational study. NervGen expects to complete patient enrollment by the second half of 2027 and release initial data in the first half of 2028.
Written for “NervGen Clinical Trial Update” on 2026-10-12,
grounded in this article and the 0 other(s) covering the same event.
- RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury
- Study builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the Phase 3 registrational design
- Enrollment completion anticipated in the second half of 2027; topline data expected in the first half of 2028
MIAMI, Oct. 12, 2026 (GLOBE NEWSWIRE) —
asserted
data → evaluate → 2028
NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the first participant has been dosed in RESTORE, a Phase 3 registrational study evaluating NVG-291 in individuals living with chronic cervical motor-incomplete SCI.
asserted
participant → develop → SCI
NervGen anticipates completing enrollment in the second half of 2027 and reporting topline data in the first half of 2028.
asserted
NervGen → complete → 2028
The Aporia
